Latest studies
- RecruitingPHASE2
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
This study is testing a new eye drop and an injection for a common cause of vision loss called Geographic Atrophy (GA), linked to Age-related Macular Degeneration (AMD). It aims to see how well these treatments work and if they are safe for people aged 55 and over.
Geographic Atrophy (GA)Age - Related Macular Degeneration (AMD)Switzerland - RecruitingPHASE3
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
This study compares a new medicine, empasiprubart, with standard IVIg treatment for adults with CIDP. It looks at how well they work and if they are safe. Participants will receive one of these treatments, or a dummy treatment, for several months.
Chronic Inflammatory Demyelinating PolyneuropathyCIDPCIDP - Chronic Inflammatory Demyelinating PolyneuropathySwitzerland - Active not recruitingPHASE3
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
This study compared two oral medications, asciminib and nilotinib, for adults newly diagnosed with a type of blood cancer called Philadelphia chromosome-positive chronic myeloid leukemia (CML). It looked at how well people tolerated each drug.
Philadelphia Chromosome-Positive Chronic Myeloid LeukemiaSwitzerland - RecruitingPHASE3
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is testing a new medicine, riliprubart, against the usual treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It's for adults already receiving IVIg to see if riliprubart works safely and effectively to manage their condition.
Chronic Inflammatory Demyelinating PolyneuropathySwitzerland - Active not recruitingPHASE3
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
This study is looking at a new way to give medicine for advanced melanoma. We want to see if an injection under the skin works as well as the usual drip into a vein. This might make treatment easier for patients.
MelanomaSwitzerland - Active not recruitingPHASE3
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
This study compares a new treatment, 177Lu-PSMA-617, with standard hormone therapy for advanced prostate cancer. It aims to see if the new treatment helps people live longer or keeps their cancer in check for longer, for those who haven't had certain chemotherapy.
Prostatic NeoplasmsSwitzerland - RecruitingPHASE3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
This study looks at a new medicine called remibrutinib for people with relapsing multiple sclerosis (RMS). It compares switching from their current medicine, ocrelizumab, to remibrutinib, versus staying on ocrelizumab, to see if it's safe and works well.
Relapsing Multiple SclerosisSwitzerland - RecruitingNA
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
This study looks at whether a special feature in a Medtronic pacemaker can help lower high blood pressure. It compares having this feature on versus off in people who either need a pacemaker or already have one and also have high blood pressure.
HypertensionHypertension, SystolicHypertension, EssentialSwitzerland - RecruitingPHASE3
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This study compares two medicines, BGB-16673 and pirtobrutinib, for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when previous treatments haven't worked well enough. It aims to see which medicine is safer and more effective.
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaSwitzerland - Active not recruitingPHASE2
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
This study is testing a new medicine, volixibat, for people with Primary Sclerosing Cholangitis (PSC) who experience bothersome itching. It aims to see if the medicine can reduce itching and affect how PSC progresses.
Primary Sclerosing CholangitisSwitzerland - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesSwitzerland - Recruiting
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
This study looks at people who need a new heart valve after their first TAVI valve wears out. We're studying a keyhole procedure called 'Redo TAVI' (putting a new valve inside the old one), along with other treatments, to find the best ways to help patients.
Aortic Valve StenosisSwitzerland - RecruitingPHASE3
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
This study is testing a new drug, neladalkib, for people with a common type of lung cancer (NSCLC) that's ALK-positive. It's comparing neladalkib to a standard treatment, alectinib, to see if neladalkib works better at stopping the cancer from growing.
Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positiveSwitzerland - RecruitingPHASE3
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
This study compares two new treatments, brelovitug and bulevirtide, for chronic Hepatitis Delta. It aims to see which is more effective for people with this liver condition, helping us find better long-term solutions.
Chronic Hepatitis D InfectionSwitzerland - RecruitingPHASE2, PHASE3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
This study is for people with a type of lung cancer that has a specific gene change (EGFR mutation) and has not responded to previous treatment. It compares a new medicine called Iza-bren with standard chemotherapy (carboplatin or cisplatin plus pemetrexed) to see which works better.
Non-Small Cell Lung CancerSwitzerland - Active not recruitingPHASE3
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
This study looks at new drug combinations for advanced liver cancer that has already been treated. It compares atezolizumab with lenvatinib or sorafenib against lenvatinib or sorafenib alone, to see if the combinations work better and are safe.
Unresectable Hepatocellular CarcinomaSwitzerland - Active not recruitingPHASE2
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
This study is testing a new medicine, Volixibat, for people with Primary Biliary Cholangitis (PBC) who experience bothersome itching. We want to see if Volixibat can reduce itching and if it affects how PBC develops. It's a Phase 2 study, meaning we're still learning about its effects.
Primary Biliary CholangitisPBCSwitzerland - RecruitingPHASE2, PHASE3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
This study looks at a new drug called adagrasib, on its own and with another drug, pembrolizumab, for people with advanced lung cancer. It's for those with a specific gene change (KRAS G12C) who haven't had treatment yet.
Advanced Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung CancerSwitzerland - RecruitingPHASE3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
This study, called LUNAR-2, is looking at a new treatment for advanced lung cancer. It combines a device called NovoTTF-200T with standard immunotherapy (pembrolizumab) and chemotherapy to see if it helps people live longer and stops cancer from growing.
Metastatic Non-small Cell Lung CancerSwitzerland - Active not recruitingPHASE3
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
This study looks at a new drug, tafasitamab, alongside standard treatments for follicular lymphoma and marginal zone lymphoma that have come back or not responded well. It aims to see if adding this new drug works better than the usual treatment alone.
Follicular LymphomaMarginal Zone LymphomaSwitzerland - Enrolling by invitation
International Registry of Congenital Portosystemic Shunt (IRCPSS)
This study is gathering information worldwide on a rare condition called Congenital Portosystemic Shunt (CPSS). It aims to better understand how CPSS affects people, why some develop serious problems, and how best to manage it. This will help improve care for those with CPSS.
Congenital Portosystemic ShuntCPSS (Congenital Portosystemic Shunt)Switzerland - Active not recruitingPHASE3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
This study is looking at a new drug, quizartinib, combined with standard chemotherapy for adults recently diagnosed with a specific type of leukaemia called AML. We want to see if this combination improves treatment outcomes compared to chemotherapy alone.
LeukemiaSwitzerland - Active not recruitingPHASE3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
This study looks at a new way to treat a type of leukaemia (blood cancer) called B-cell precursor acute lymphoblastic leukaemia (ALL) in older adults. It compares a drug called Blinatumomab combined with gentler chemotherapy against the usual chemotherapy treatment to see which works best.
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Switzerland - Active not recruitingPHASE3
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
This study is looking at new ways to treat a type of breast cancer that doesn't have certain hormone receptors or HER2 protein, called triple-negative or hormone receptor-low/HER2-negative breast cancer. It tests two different treatment plans using new and existing medicines before and after surgery.
Breast CancerSwitzerland - RecruitingPHASE1
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
This study is looking at a new medicine called Inno8 for people with haemophilia A. Its main goal is to check how different amounts of the medicine work and if it's safe. It's a short study lasting about 11 weeks.
Haemophilia ASwitzerland - Active not recruitingPHASE3
Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients
This study compares two treatments for a type of slow-growing lymphoma called Splenic Marginal Zone Lymphoma (SMZL). It looks at whether a combination of two drugs, rituximab and zanubrutinib, works better and is as safe as rituximab alone for patients needing their first treatment.
Splenic Marginal Zone LymphomaSwitzerland - RecruitingPHASE3
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
This study is testing a new medicine, cladribine, in pill form for people with a muscle weakening condition called myasthenia gravis. We want to see if it helps and if it's safe compared to a dummy pill. We're also looking at its long-term effects and how the body uses the medicine.
Generalized Myasthenia GravisSwitzerland - RecruitingPHASE2, PHASE3
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
This study is testing a new medicine, efgartigimod PH20 SC, for children aged 2 to 17 with a muscle weakness condition called generalised Myasthenia Gravis. We want to find the best dose and make sure it's safe. Participants will get injections and be monitored.
Generalized Myasthenia GravisSwitzerland - Active not recruitingPHASE3
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
This study is testing a new medicine, tulisokibart, for people with moderate to severe ulcerative colitis. It aims to see if the medicine can help people feel better and stay in remission, compared to a dummy medicine, both in the short and long term.
Ulcerative ColitisSwitzerland - RecruitingPHASE4
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
This study looks at how well a medicine called pegcetacoplan works and if it's safe for people in the UK with rare kidney diseases like C3G or IC-MPGN. It uses real-life information from patients to help doctors make better decisions about treatment.
C3 Glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)Switzerland - RecruitingPHASE3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
This study is for people who have already taken part in other studies for a medicine called sotatercept, used to treat Pulmonary Arterial Hypertension (PAH). It aims to check the long-term safety and how well people tolerate sotatercept when taken with their usual PAH treatments.
Pulmonary Arterial HypertensionSwitzerland - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseSwitzerland - Active not recruitingPHASE3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.
Crohn's DiseaseSwitzerland - Active not recruitingPHASE3
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
This study looks at the long-term safety of a new medicine called Nemolizumab for people with Prurigo Nodularis. It's for those who have already tried Nemolizumab in a previous study for this skin condition.
Prurigo NodularisSwitzerland - RecruitingPHASE3
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine called Duvakitug for people with Crohn's disease that isn't well controlled. It compares Duvakitug to a dummy medicine to see if it's safe and effective in improving symptoms for those with moderately to severely active Crohn's.
Crohn's DiseaseSwitzerland - RecruitingPHASE3
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
This study is testing a new medicine, Ris-Rez, for advanced small cell lung cancer that has come back. It aims to see if Ris-Rez works better than standard treatment (topotecan) to shrink tumours and help people live longer, while also checking its safety.
Neoplasms, LungSwitzerland - Active not recruitingPHASE3
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
This study is for people with cancer who are already receiving specific cancer treatments in another study. It allows them to continue their treatment if their original study ends and they can't get the medicine elsewhere. It's about safely extending access to these important cancer drugs.
CancerSwitzerland - RecruitingPHASE3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
This study looks at a new medicine called obrixtamig for advanced small cell lung cancer. It compares obrixtamig plus standard treatment against standard treatment alone to see if it helps people live longer. It also tests a device to measure a cancer marker.
Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)Switzerland - Active not recruitingPHASE3
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
This study for advanced kidney cancer compares a standard treatment, Sunitinib, with two new combinations: Lenvatinib plus Everolimus, or Lenvatinib plus Pembrolizumab. The aim is to see if either new combination can keep the cancer from growing for longer. It's in the final stage of testing.
Renal Cell CarcinomaSwitzerland - RecruitingPHASE2
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
This study is looking at a new medicine called ALN-APP for a condition called Cerebral Amyloid Angiopathy (CAA). It aims to see how well ALN-APP works to slow down CAA and if it's safe. Participants will either receive the new medicine or a dummy treatment.
Cerebral Amyloid AngiopathySwitzerland - Active not recruitingPHASE2
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
This study looks at a new medicine called lutikizumab for adults with moderate to severe ulcerative colitis. It aims to see if it's safe and how well it works compared to a common treatment called adalimumab.
Ulcerative ColitisSwitzerland - Active not recruitingPHASE3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.
Cardiovascular Disease and Lipoprotein(a)Switzerland - Active not recruitingPHASE3
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
This study is looking at how well two new drugs, enfortumab vedotin and pembrolizumab, work together to treat advanced bladder cancer that has spread. It compares them to standard chemotherapy treatments to see if they are a better option.
Urothelial CancerSwitzerland - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
CancerSwitzerland - RecruitingPHASE1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This study is testing a new drug called sigvotatug vedotin for people with several types of advanced cancer. Researchers want to see if it's safe, what side effects it causes, and if it can help treat cancer, sometimes in combination with other common cancer medicines.
Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast NeoplasmsEsophageal Squamous Cell CarcinomaSwitzerland - Not yet recruitingNA
Effectiveness of an Interprofessional Approach to the Treatment of Spasticity With Botulinum Toxin & Non-pharmacological Therapies
This study looks at how well a team approach works for treating muscle stiffness (spasticity) using Botox injections and other therapies. Researchers want to see if combining these treatments helps people reach their personal goals and improve their daily lives.
SpasticitySwitzerland - Active not recruitingPHASE3
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
This study compares a new cancer drug called sigvotatug vedotin with a standard treatment, docetaxel, for advanced non-small cell lung cancer that has previously been treated. It aims to see if the new drug works better and what side effects it might cause.
Carcinoma, Non-Small-Cell LungSwitzerland - Active not recruitingPHASE3
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
This study is testing a new drug, elafibranor, for people with a liver condition called Primary Biliary Cholangitis (PBC). It aims to see if the drug can improve liver health and reduce symptoms like itching and tiredness compared to a dummy treatment.
Primary Biliary CirrhosisSwitzerland - RecruitingPHASE4
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
This study looks at whether blood-thinning medicines (anticoagulants) can prevent strokes and other heart-related problems in people who have had temporary episodes of an irregular heartbeat called atrial fibrillation (AF) during stressful times like surgery or serious illness.
StrokeAtrial FibrillationSwitzerland - Active not recruitingPHASE3
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
This study looks at a new drug, Tarlatamab, for people with a type of lung cancer called limited-stage small-cell lung cancer (LS-SCLC). It aims to see if Tarlatamab can help people live longer without their cancer getting worse after chemotherapy and radiotherapy.
Limited Stage Small Cell Lung CancerSmall Cell Lung CancerSwitzerland